Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01485614

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01485614
  • EudraCT 2011-002528-42
Other papers using this trial's data
  • A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes Pediatric diabetes, 2022-03 DOI, PubMed 34779087

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01485614. Randomized; double masking; primary purpose treatment. Start 2012-02-10 (actual); primary completion 2019-10-09 (actual). Results posted on 2020-12-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
Condition
Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to sitagliptin
Intervention (Drug)
Placebo to metformin
Intervention (Drug)
Glycemic Rescue 1
Intervention (Biological)
Glycemic Rescue 2
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01485614
Content hash
e0a002dfbb36d80128e3518fb11d74146e3373bf27a8dc671d9152e794ca4b3e